Clario, a US provider of endpoint data solutions to the clinical trial industry, announced on Monday that it has acquired NeuroRx, a Canada-based provider of imaging analysis with expertise in multiple sclerosis.

Financial terms of the deal were not disclosed.

Clario's chief executive officer, Chris Fikry, MD, said: "We're excited to welcome NeuroRx to Clario. This strategic acquisition reinforces our strong leadership in imaging and further expands our capabilities in neuroscience -- an area of immense importance in advancing medical innovation. By augmenting our expertise in this critical therapeutic area, we are even better positioned to support our customers in developing life-changing drugs."

Clario has named Douglas Arnold, MD, NeuroRx's founder and chief executive officer, as senior scientific advisor.

Last week, Clario agreed to acquire WCG's eCOA business. Together, the two acquisitions are expected to strengthen the company's scientific expertise and service delivery capabilities in the neuroscience therapeutic area.